# P2Y14 receptor activation and neutrophil signaling: linking inflammation to systemic pathophysiology

**Authors:** Renan da Silva Ebone, Pedro Henrique Doleski, Matheus Henrique Jantsch, Rafaella Pereira da Silveira, Daniela Bitencourt Rosa Leal

PMC · DOI: 10.1007/s11302-025-10113-7 · 2026-01-15

## TL;DR

This paper reviews how the P2Y14 receptor influences neutrophil activity in inflammation and disease, suggesting it could be a target for reducing harmful immune responses.

## Contribution

The paper provides a comprehensive review of P2Y14 receptor signaling in neutrophils and its implications in inflammation and disease.

## Key findings

- P2Y14 receptor activation modulates neutrophil chemotaxis and oxidative responses via Gi/o and RhoA signaling.
- P2Y14 is implicated in diseases like glioblastoma and COVID-19 through increased neutrophil infiltration and inflammation.
- Targeting P2Y14 may help mitigate harmful inflammatory responses and tissue damage.

## Abstract

Neutrophils are essential effector cells of the innate immune system, acting as the first line of defense against infection and tissue injury. Among the purinergic receptors expressed in these cells, P2Y14 has gained increasing attention in recent years for its role in modulating neutrophil recruitment and activation in inflammatory contexts. This receptor is activated mainly by uridine diphosphoglucose (UDP-glucose) and other UDP-sugars released during cellular stress or damage. Through the activation of G protein–coupled pathways, particularly via Gi/o and RhoA signaling, P2Y14 influences key neutrophil functions, including chemotaxis, cytoskeletal rearrangements, and oxidative responses. Despite its pro-inflammatory potential, and the increasing amount of literature data in recent years, P2Y14’s complete physiological and pathological roles remain underexplored. Literature data also highlight its involvement in diseases like glioblastoma and COVID-19, where, due to increased neutrophil infiltration, it exacerbates inflammation, tissue damage, and stress. Therefore, targeting P2Y14 may be a promising strategy to modulate neutrophil chemotaxis and mitigate unwanted harmful inflammatory responses. This review discusses the characteristics and signaling mechanisms of P2Y14 in neutrophils, as well as the relevant implications of this pathway for neutrophil function.

## Linked entities

- **Genes:** P2RY14 (purinergic receptor P2Y14) [NCBI Gene 9934]
- **Proteins:** P2RY14 (purinergic receptor P2Y14), RHOA (ras homolog family member A)
- **Chemicals:** uridine diphosphoglucose (PubChem CID 8629), UDP-glucose (PubChem CID 8629)
- **Diseases:** glioblastoma (MONDO:0018177), COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, P2RY14 (purinergic receptor P2Y14) [NCBI Gene 9934] {aka BPR105, GPR105, P2Y14}
- **Diseases:** infection (MESH:D007239), tissue injury (MESH:D017695), glioblastoma (MESH:D005909), inflammation (MESH:D007249), COVID-19 (MESH:D000086382)
- **Chemicals:** UDP-glucose (MESH:D014532), UDP-sugars (MESH:D014539)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12804551/full.md

---
Source: https://tomesphere.com/paper/PMC12804551